NCT06434961View on ClinicalTrials.gov

The Trial of SHR6508 in Secondary Hyperparathyroidism

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

498

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

SHR6508 plus oral placebo tablets

SHR6508 plus oral placebo tablets

DRUG

Cinacalcet plus intravenous placebo

Cinacalcet plus intravenous placebo

Trial Locations (1)

510000

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

NCT06434961 - The Trial of SHR6508 in Secondary Hyperparathyroidism | Biotech Hunter | Biotech Hunter